2-[[2-(3-Cyano-4,6-diphenylpyridin-2-yl)sulfanylacetyl]amino]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[2-(3-Cyano-4,6-diphenylpyridin-2-yl)sulfanylacetyl]amino]acetic acid
• 化学式: C₂₂H₁₇N₃O₃S
• 分子量: 403.5
• InChiKey: YODWGXJRYRIPJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors
  作者：Stephanie M. Myers、Ruth H. Bawn、Louise C. Bisset、Timothy J. Blackburn、Betty Cottyn、Lauren Molyneux、Ai-Ching Wong、Celine Cano、William Clegg、Ross. W. Harrington、Hing Leung、Laurent Rigoreau、Sandrine Vidot、Bernard T. Golding、Roger J. Griffin、Tim Hammonds、David R. Newell、Ian R. Hardcastle

  DOI：10.1021/acscombsci.5b00155

  日期：2016.8.8

  The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57 617 compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits demonstrated that one series did not return active

  细胞外相关激酶5（ERK5）是癌症治疗的有希望的目标。基于IMAP FP渐进结合系统，针对ERK5开发了高通量筛选，并用于从57 617种化合物的文库中鉴定命中。筛选命中明显有四个不同的化学系列。命中的重新合成和重新测定表明，一个系列没有返回活性化合物，而三个系列返回了活性命中。结构活性研究表明，4-苯甲酰基吡咯-2-羧酰胺药效团具有很好的进一步开发潜力。鉴定了最小的激酶结合药效基团，关键实例证明了对ERK5的选择性优于p38α激酶。
• Glyoxalase inhibitors
  申请人：Ashton Mark

  公开号：US20070015799A1

  公开（公告）日：2007-01-18

  This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase 1. Wherein X is N or CH. R 2 is H, CF 3 ; or optionally substituted C 5-6 aryl, C 3-7 cycloalkyl, C 5-7 heterocyclyl. R 3 is H; or optionally substituted C 5-6 aryl, C 3-7 cycloalkyl, C 5-7 heterocyclyl. Alternatively R 2 and R 3 together form an optionally substituted C 3-4 alkylene group wherein L 3 and L 4 are single bonds thus forming a C 5-6 ring fused with the aromatic ring to which L 3 and L 4 are attached. L 3 and L 4 are independently selected from a single bond, optionally substituted C 1-4 alkylene, -L 9 YN(OH)C(═O)L 10 - and -L 9 C(═O)N(OH)YL 10 -, wherein L 9 and L 10 are independently selected from optionally substituted C 1-4 alkylene, C 5-6 arylene, C 1-4 alkylene-C 5-6 arylene and a single bond, wherein Y is NH or a single bond.

  本发明涉及式(I)的化合物，它们是乙二醛酶I抑制剂，包括此类化合物的药物盐或组合物，以及使用这种组合物和化合物来治疗通过抑制乙二醛酶1缓解的各种疾病。其中X是N或CH。R2为H、CF3；或者是可选取代的C5-6芳基、C3-7环烷基、C5-7杂环基。R3为H；或者是可选取代的C5-6芳基、C3-7环烷基、C5-7杂环基。或者R2和R3一起形成一个可选取代的C3-4烷基，其中L3和L4是单键，从而形成一个与L3和L4连接的芳环。L3和L4分别独立选择自单键、可选取代的C1-4烷基、-L9YN(OH)C(═O)L10-和-L9C(═O)N(OH)YL10-，其中L9和L10分别独立选择自可选取代的C1-4烷基、C5-6芳基、C1-4烷基-C5-6芳基和单键，其中Y为NH或单键。